Work

Adjuvant capecitabine and trastuzumab for stage IA HER2-positive breast cancer (IRIS-A): A phase II clinical trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.508

Authors: Ruoxi Wang, Min He, Li Chen, Linxiaoxi Ma, Guangyu Liu, Keda Yu, Lei Fan, Zhonghua Wang, Zhi-Ming Shao

Institutions: Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Fudan University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162571452

Cites:

Cited by: 3

Related to: